Heart Institute

University of Montreal Pharmacy Department Fellow in Cardiovascular Research Montreal Heart Institute Montreal Quebec, Canada... 

Deborah DeEugenio, Pharm.D., B.C.P.S., is a 2001 graduate of the Philadelphia College of Pharmacy at the University of the Sciences (Philadelphia). She completed a residency in Pharmacy Practice at Thomas Jefferson University Hospital (Philadelphia). Dr. DeEugenio is a member of the Temple University School of Pharmacy faculty as a Clinical Assistant Professor and a Certified Antithrombotic Provider and a Board Certified Pharmacotherapy Specialist. Her clinical activity takes place at Jefferson Heart Institute as part of the Jefferson Antithrombotics Therapy Service. The ambulatory clinic serves 400 patients on chronic anticoagulation therapy and provides continuous monitoring and education to these patients. The clinic also provides drug information and pharmacy support to the physicians and other health-care providers at the Institute. 

Emerson C. Perin, MD, PhD Stem Cell Center, Texas Heart Institute, St. Luke s Episcopal Hospital, Houston, TX, USA... 

Texas Heart Institute, St. Luke s Episcopal Hospital,... 

Table 6.1 Effect of TandemHeart use on various parameters in refractory cardiogenic shock—Texas Heart Institute experience...

Finally, at the Texas Heart Institute, we are developing a concept device that will consist of a catheter deployed micropump in the descending aorta and fixated with metallic struts to the aortic wall. It is designed to accelerate blood flow in the descending aorta to unload the heart. Its power will be supplied through a transarterial power cable to an outside power source. Though still in the conceptual phase only, it may be truly implantable in the cath lab without surgery. 

Reynolds Delgado Texas Heart Institute Houston, TX 77225-0345 USA... 

The current situation is exemplified by a study of clinical staff exposures in cardiac angiography at the Montreal Heart Institute (Renaud, 1992). Extensive measurements of staff exposures were made using thermoluminescent dosimeters (TLDs) for 15,000 procedures in three cardiac catheterization laboratories over a 5 y period (1984 to 1988). The TLDs were located under the protective apron at the waist and at the collar outside and above the apron. Readings were made at three-month intervals, with a minimum reportable value of 0.2 mSv. Average values (in mSv per y) for various groups of staff, based on measurements with TLDs worn at the collar, are given in Table 3.3. 

Gerontology Branch, National Heart Institute, National Institutes of Health, U. S. Department of Health, Education and Welfare,... 

Merker, R. L., Eliash, L. J., Mayhew, S. H., Wang, J. Y. C. Artificial Heart Program Conference Proceedings. Ed. Hegyeli, R. J., Washington National Heart Institute Artificial Heart Program 1969 p. 29... 

Supported by a grant-in-aid from the National Heart Institute, U. S. Public Health Service. 

Heart Care Associates Milwaukee Heart Institute Milwaukee Wl USA... 

Deborah DeEugenio holds a Doctor of Pharmacy degree from the University of the Sciences in Philadelphia, Philadelphia College of Pharmacy. She completed a post- doctoral residency in pharmacy practice at Thomas Jefferson University Hospital. Dr. DeEugenio is a Board Certified Pharmacotherapy Specialist and a Certified Anticoagulation Provider. Dr. DeEugenio is currently an Assistant Professor at Temple University School of Pharmacy in Philadelphia. She also works at Thomas Jefferson University Hospital as a clinical pharmacist for Jefferson Heart Institute and Jefferson Antithrombotics Therapy Service. 

Acknowledgments The work described was supported by the Medical Research Council of South Africa, the Harry Crossley Fund, Stellenbosch University, and the Cape Heart Institute. 

Departement de Physiologie, Universite de Montreal, Montreal, QC, Canada, and the Montreal Heart Institute, Montreal, QC, Canada... 

Research Center, Montreal Heart Institute, University of Montreal,... 

We gratefully acknowledge the support provided us by the National Heart Institute of the National Institutes of Health, through Contract No. 

HEART- 2DPAGE German Heart Institute, Berlin Human heart (ventricle) Human heart (atrium) http //userpage.chemie.fu-berlin.de/ pldss/dhzb.html Pleissner et al., 1996... 

RAT HEART-2DPAGE German Heart Institute, Berlin Rat heart http //www.mpiib- berlin.mpg.de/2D-PAGE/ RAT-HEART/2d/ U et al., 1999... 

Recent investigatioins at the National Heart Institute, Bethesda, Maryland, and the Rockefeller Institute for Medical Research, New York, indicate that the sequence of ribonuclease involving residues 11 through 18 is incorrect as shown in Fig. 17. The correct sequence will be published shortly by both of the laboratories (personal communication from C. B. Anfinsen). 

Fig. 19. Topography of the NBS cleavage of the six tyrosyl peptide links of native and

I am greatly obligated to my colleagues and associates at the National Institutes of Health who contributed experimentally, conceptually, and editorially to this chapter. Special thanks are due to Drs. L. A. Cohen, E. Gross, and W. B. Lawson. Dr. C. B. Anfinsen, National Heart Institute, and Drs. A. Berger, A. Patchornik, and M. Sela from the Weizmann Institute were extremely helpful in making unpublished material available prior to publication. To them and many other cooperative authors I extend my sincere thanks. 

Dopamine (DO) was discovered by Arvid Carlsson and Jils-Ake Hillarp at the Laboratory for Chemical Pharmacology of the National Heart Institute of Sweden, in 1952. 

For over 25 years, Dr. Friedewald practiced internal medicine and cardiology, initially in 1971 as Director of Diagnostic Laboratories at the Arizona Heart Institute in Phoenix. In 1976 he assumed the position of Chief of Cardiology and Chairman of the Department of Internal Medicine at the Honolulu Medical Group at Queen s Medical Center in Honolulu. He returned to Houston in 1982 to practice cardiology as a member of the faculty at Baylor and serve as Director of the Cardiac Noninvasive Laboratory and the Cardiac Rehabilitation Program at the Kelsey-Seybold Clinic. 

Invited Professor, Faculty of Pharmacy, University of Montreal, Fellow in Cardiovascular Research, Montreal Heart Institute, Montreal, Quebec, Canada Chapter 16... 

In the past few years, the chemistry and pharmacology of the catecholamines and their metabolic inhibitors have been the subject of intensive investigation in many parts of the world but especially by Sjoerdsma and Axelrod at the National Heart Institute. Monoamine oxidase inhibitors have been tried in the treatment of hypertension with both uncertain results and uncertain rationale. Recently, the decarboxylase inhibitor, methyldopa, has been widely recommended in the treatment of hypertension, though, again, the evidence gives no clear idea as to how it works. 

---